NCT00437424View on ClinicalTrials.gov

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Brivanib

Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression

Trial Locations (5)

35294

University Of Alabama At Birmingham, Birmingham

41013

Local Institution, Seville

44106

Case Western Reserve University, Clleveland

78229

South Texas Accelerated Research Therapeutics, Llc, San Antonio

90033

Usc/Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY